Introduction
Although BI in the earlier stages of drug development remains an emergent
solution area in the pharmaceutical market, contextual forces such as pipeline
productivity pressures and growing generic competition will drive increased
spending on BI in the near future.
Scope
- Identifies potential growth areas for technology in Big Pharma in Europe
- Quantifies spending on BI solutions by pharmaceutical end-user segments
- Segments IT spending by technology, country and end-user group
Report Highlights
The adoption of BI solutions will exhibit strong growth over the next five
years.
The Biotech segment will increase their spending on BI solutions more quickly
than Big Pharma
BI adoption by clinical end-user groups will demonstrate the most rapid growth
compared to R&D, manufacturing and sales & marketing groups.
Reasons to Purchase
- Understand the potential opportunity size for BI solutions in the
pharmaceutical market.
- Identify the BI technology areas in which pharmaceutical companies will
invest the most heavily.
- Recognize the differences in BI spending across segments of the market and
end-user groups.
View Cart
